
PLRX Valuation
Pliant Therapeutics Inc
- Overview
- Forecast
- Valuation
- Earnings
PLRX Relative Valuation
PLRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PLRX is overvalued; if below, it's undervalued.
Historical Valuation
Pliant Therapeutics Inc (PLRX) is now in the Fair zone, suggesting that its current forward PS ratio of 53.01 is considered Fairly compared with the five-year average of -5.54. The fair price of Pliant Therapeutics Inc (PLRX) is between 0.56 to 14.27 according to relative valuation methord.
Relative Value
Fair Zone
0.56-14.27
Current Price:1.59
Fair
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
0.38
P/B
Median3y
2.27
Median5y
2.53
-183.36
FCF Yield
Median3y
-36.67
Median5y
-26.34
Competitors Valuation Multiple
The average P/S ratio for PLRX's competitors is 11.96, providing a benchmark for relative valuation. Pliant Therapeutics Inc Corp (PLRX) exhibits a P/S ratio of 53.01, which is 343.29% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
People Also Watch

SVM
Silvercorp Metals Inc
4.770
USD
-1.45%

WSR
Whitestone REIT
12.530
USD
-0.16%

UFCS
United Fire Group Inc
26.900
USD
-3.31%

VHI
Valhi Inc
17.330
USD
-2.20%

THRY
Thryv Holdings Inc
11.760
USD
-2.65%

SMP
Standard Motor Products Inc
32.970
USD
-0.78%

ORC
Orchid Island Capital Inc
7.300
USD
-0.54%

ZIP
Ziprecruiter Inc
4.590
USD
-1.71%

PHAR
Pharming Group NV
10.191
USD
+0.90%

ORIC
Oric Pharmaceuticals Inc
11.730
USD
-0.59%
FAQ

Is Pliant Therapeutics Inc (PLRX) currently overvalued or undervalued?
Pliant Therapeutics Inc (PLRX) is now in the Fair zone, suggesting that its current forward PS ratio of 53.01 is considered Fairly compared with the five-year average of -5.54. The fair price of Pliant Therapeutics Inc (PLRX) is between 0.56 to 14.27 according to relative valuation methord.

What is Pliant Therapeutics Inc (PLRX) fair value?

How does PLRX's valuation metrics compare to the industry average?

What is the current P/B ratio for Pliant Therapeutics Inc (PLRX) as of Jul 25 2025?

What is the current FCF Yield for Pliant Therapeutics Inc (PLRX) as of Jul 25 2025?

What is the current Forward P/E ratio for Pliant Therapeutics Inc (PLRX) as of Jul 25 2025?
